Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) EBITDA Margin (2024 - 2025)

Monte Rosa Therapeutics (GLUE) has 2 years of EBITDA Margin data on record, last reported at 211.11% in Q3 2025.

  • For Q3 2025, EBITDA Margin rose 4400.0% year-over-year to 211.11%; the TTM value through Sep 2025 reached 11.03%, up 81407.0%, while the annual FY2024 figure was 96.97%, N/A changed from the prior year.
  • EBITDA Margin reached 211.11% in Q3 2025 per GLUE's latest filing, down from 53.2% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 55.24% in Q1 2025 and bottomed at 3001.6% in Q1 2024.